AgomAb Therapeutics NV AGMB
Annual
Quarterly
No annual revenue total was found in AgomAb Therapeutics NV's SEC filings.
AgomAb Therapeutics NV (AGMB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
34.17M
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Belgium
- Headquarters
- Antwerpen
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2020932
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Oct 1, 2026 | Oct 1, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
| 6-K | Current report (foreign issuer) | Aug 10, 2026 | Aug 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 6, 2026 |
All 49 AgomAb Therapeutics NV SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.